CG Oncology Presents Interim Results of CG0070 + Keytruda (pembrolizumab) in P-II (CORE1) Study for NMIBC Unresponsive to Bacillus Calmette-Guerin at AACR 2022
Shots:
- The P-II (CORE1) study to evaluate the safety & efficacy of G0070 + Merck’s Keytruda in ~35 patients with NMIBC unresponsive to BCG
- As data cutoff on Apr 7, 2022, 18 patients were evaluable for efficacy, 89% achieved CR at the initial 3mos., 85% maintained a CR @6mos., 78% @9mos. & 75% @12mos. assessment, was well tolerated with an encouraging early efficacy data, treatment-related AEs were generally limited to transient grade 1-2 local genitourinary symptoms, no treatment-related grade 3 or higher AEs or SAEs have been observed
- CG0070 is currently being evaluated in late-stage clinical trials across multiple solid cancers as monothx. or in combination with immune checkpoint inhibitors
Ref: Businesswire | Image: Businesswire
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
